Evidence map›Paper›PMID 42337315›Full record

ArticleNPJ precision oncology2026

ImmuGT-ConRes: a consistency learning residual network for predicting pan-cancer immunotherapy response from gene expression data.

Keru Ma, Hao Wang, Genshen Mo, Hao Li, Xinyue Zhang, Meihong Yan, Jialin Wang, Junchao Shao, Haonan Xie, Yuze Huang and 4 more

Abstract read
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Keru Ma *Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Hao Wang *Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Genshen Mo *Department of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Hao LiDepartment of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Xinyue ZhangDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Meihong YanDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Jialin WangDepartment of Science, Computer Science, University of Alberta, Edmonton, AB, Canada.
Junchao ShaoDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Haonan XieDepartment of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Yuze HuangDepartment of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Huiying LiDepartment of Pathology, Harbin Medical University Cancer Hospital, Harbin, China.
Dalin LiDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China. lidalin1975@163.com.
Peng HanDepartment of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, China. leospiv@hrbmu.edu.cn.
Shenghan LouDepartment of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, China. lou1219@126.com.

Funding

China Postdoctoral Science Foundation 2023MD744213Heilongjiang Provincial Natural Science Foundation of China (LH2023H096) LH2023H096Postdoctoral research project in Heilongjiang Province (LBHZ22210) LBHZ22210Scientific research project of Heilongjiang Provincial Health Commission (20230404080339) 20230404080339
6 · The paper itself

Abstract

Immunotherapy is leading the transformation in cancer treatment, but its response rate remains low, and there is a scarcity of immune targets that can produce lasting effects. Multi-omics data is widely used in immunotherapy. However, traditional analysis methods often struggle to uncover hidden correlations within the data, limiting the exploration of potential immunotherapy targets. Here, we pooled immunotherapy data from over 40 cohorts and developed ImmuGT-ConRes (Genomic Image Transformation with Consistency Learning and Residual Networks). ImmuGT-ConRes uses a contrastive learning approach, incorporating a dual-branch data augmentation strategy and a multi-scale stride convolution structure. By integrating residual networks and attention mechanisms, ImmuGT-ConRes adapts to multi-scale gene feature capture, reduces information loss between shallow details and deep semantics, and enhances the model's robustness to input perturbations. We demonstrated that ImmuGT-ConRes exhibited superior predictive performance and provided interpretability by ranking gene weights based on the attention mechanism, providing an effective approach for immunotherapy target mining. These results suggest that ImmuGT-ConRes offers a promising framework for immunotherapy target discovery and merits further investigation.

Identifiers

PMID42337315
PMCPMC13655099

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.